
Accelerant Holdings Announces Pricing of Upsized Initial Public Offering
Morgan Stanley & Co. LLC is acting as lead left active bookrunner, Goldman Sachs & Co. LLC is acting as lead right active bookrunner, and BMO Capital Markets Corp. and RBC Capital Markets, LLC are acting as active bookrunners for the offering. Wells Fargo Securities, LLC, Piper Sandler & Co., William Blair & Company, L.L.C., Raymond James & Associates, Inc. and TD Securities (USA) LLC are acting as bookrunners. Citizens Capital Markets and FT Partners are acting as co-managers.
The offering of Accelerant's Common Shares is being made only by means of a prospectus. When available, copies of the final prospectus relating to the offering may be obtained for free by visiting EDGAR on the U.S. Securities and Exchange Commission's (the 'SEC') website at www.sec.gov. Alternatively, copies of the final prospectus may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@morganstanley.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; BMO Capital Markets Corp., Attention: Equity Syndicate Department, 151 W 42nd Street, 32nd Floor, New York, NY 10036, by telephone at (800) 414-3627, or by email at bmoprospectus@bmo.com; RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New York, NY 10281, by telephone at (877) 822-4089, or by email at equityprospectus@rbccm.com.
A registration statement on Form S-1 relating to the Common Shares was declared effective by the SEC on July 23, 2025. This press release does not constitute an offer to sell or the solicitation of an offer to buy Common Shares, and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.
ABOUT ACCELERANT
Accelerant is a data-driven risk exchange connecting underwriters of specialty insurance risk with risk capital providers. Accelerant was founded in 2018 by a group of longtime insurance industry executives and technology experts who shared a vision of rebuilding the way risk is exchanged – so that it works better, for everyone. The Accelerant risk exchange does business across 22 different countries and more than 500 specialty insurance products.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
The V-shaped recovery in stocks is a V-shaped recovery in earnings: Chart of the Week
The S&P 500 (^GSPC) notched five record highs in as many trading days last week, capping off what's now a 28% rally since reaching this year's lows on April 8. This V-shaped recovery in the benchmark index marks the second-fastest rebound from a drawdown of at least 19% in the last 75 years, according to data from Creative Planning's chief strategist Charlie Bilello. A massive move in the index from a low of 4,987 to Friday's closing price of 6,389 has formed a large V shape in the S&P 500 2025 chart. Sign up for the Yahoo Finance Morning Brief By subscribing, you are agreeing to Yahoo's Terms and Privacy Policy And though questions may linger for some as to what, exactly, is driving the market higher, the V-shaped recovery in earnings expectations that has accompanied this rebound in the market makes this rally make a whole lot more sense. Data from Morgan Stanley's chief investment officer Mike Wilson shows that earnings revisions breadth — or the ratio of companies raising forecasts to those cutting forecasts — has rebounded as dramatically as, and in lockstep with, the S&P 500 itself. "Many market participants do not appreciate how strong this very fundamental driver has been over the past several months," Wilson told Yahoo Finance. After tanking as analysts assessed the impact of President Trump's initial "Liberation Day" tariffs, earnings revisions have been soaring. And early returns this earnings period have backed up this optimism. With 34% of the S&P 500 having reported results, earnings in the second quarter are on pace to grow 6.4%, up from the 5% expected on June 27, per FactSet data. Estimates for year-over-year earnings growth in the final two quarters of 2025 and for the full year 2026 have been moving higher. As of July 25, FactSet data showed analysts expect the S&P 500 to grow earnings by 13.9% in 2026, up from the 13.8% that had been expected a month ago. Wilson notes these revisions lead actual earnings estimates and that the current recovery in the outlook is rivaled only by the pandemic-era rebound. That period, Wilson adds, is "the last time we were so out of consensus on the market." The rebound in earnings revisions "helps to not only justify the rally to date, but also why we remain bullish on the next six to 12 months," Wilson added. "We are currently experiencing one of the strongest V-shaped recoveries in history, rivaling the COVID rebound in 2020, the last time we were so out of consensus on the market," Morgan Stanley's chief investment officer told Yahoo Finance. Wilson's chart is one of several in Yahoo Finance's upcoming Chartbook, which will be published Tuesday morning, that help explain why the S&P 500 has roared back to all-time highs despite persistent fears Trump's tariffs could derail earnings growth. Recent signs of feverish speculation in the market, notably the meme stock resurgence, could be a reason for caution. And valuations have also been on the rise — the S&P 500 is now valued at 22.4 times next year's earnings, above the five- and 10-year averages of 19.9 and 18.4. But the simple fact is that, to this point, tariffs haven't had the broad impact on corporate earnings and the US economy that many had feared. And what's more, arguably the most important driver of stock prices is again on the rise. Josh Schafer is a reporter for Yahoo Finance. Follow him on X @_joshschafer. Click here for in-depth analysis of the latest stock market news and events moving stock prices Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
The V-shaped recovery in stocks is a V-shaped recovery in earnings: Chart of the Week
The S&P 500 (^GSPC) notched five record highs in as many trading days last week, capping off what's now a 28% rally since reaching this year's lows on April 8. This V-shaped recovery in the benchmark index marks the second-fastest rebound from a drawdown of at least 19% in the last 75 years, according to data from Creative Planning's chief strategist Charlie Bilello. A massive move in the index from a low of 4,987 to Friday's closing price of 6,389 has formed a large V shape in the S&P 500 2025 chart. Sign up for the Yahoo Finance Morning Brief By subscribing, you are agreeing to Yahoo's Terms and Privacy Policy And though questions may linger for some as to what, exactly, is driving the market higher, the V-shaped recovery in earnings expectations that has accompanied this rebound in the market makes this rally make a whole lot more sense. Data from Morgan Stanley's chief investment officer Mike Wilson shows that earnings revisions breadth — or the ratio of companies raising forecasts to those cutting forecasts — has rebounded as dramatically as, and in lockstep with, the S&P 500 itself. "Many market participants do not appreciate how strong this very fundamental driver has been over the past several months," Wilson told Yahoo Finance. After tanking as analysts assessed the impact of President Trump's initial "Liberation Day" tariffs, earnings revisions have been soaring. And early returns this earnings period have backed up this optimism. With 34% of the S&P 500 having reported results, earnings in the second quarter are on pace to grow 6.4%, up from the 5% expected on June 27, per FactSet data. Estimates for year-over-year earnings growth in the final two quarters of 2025 and for the full year 2026 have been moving higher. As of July 25, FactSet data showed analysts expect the S&P 500 to grow earnings by 13.9% in 2026, up from the 13.8% that had been expected a month ago. Wilson notes these revisions lead actual earnings estimates and that the current recovery in the outlook is rivaled only by the pandemic-era rebound. That period, Wilson adds, is "the last time we were so out of consensus on the market." The rebound in earnings revisions "helps to not only justify the rally to date, but also why we remain bullish on the next six to 12 months," Wilson added. "We are currently experiencing one of the strongest V-shaped recoveries in history, rivaling the COVID rebound in 2020, the last time we were so out of consensus on the market," Morgan Stanley's chief investment officer told Yahoo Finance. Wilson's chart is one of several in Yahoo Finance's upcoming Chartbook, which will be published Tuesday morning, that help explain why the S&P 500 has roared back to all-time highs despite persistent fears Trump's tariffs could derail earnings growth. Recent signs of feverish speculation in the market, notably the meme stock resurgence, could be a reason for caution. And valuations have also been on the rise — the S&P 500 is now valued at 22.4 times next year's earnings, above the five- and 10-year averages of 19.9 and 18.4. But the simple fact is that, to this point, tariffs haven't had the broad impact on corporate earnings and the US economy that many had feared. And what's more, arguably the most important driver of stock prices is again on the rise. Josh Schafer is a reporter for Yahoo Finance. Follow him on X @_joshschafer. Click here for in-depth analysis of the latest stock market news and events moving stock prices
Yahoo
14 hours ago
- Yahoo
Morgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 17, Morgan Stanley upgraded FOLD to Overweight with a $12 price target, citing its strong intellectual property position ahead of a key legal decision with Aurobindo. A research team in lab coats testing a new ImmunoPhage platform in a modern biotechnology lab. The firm also pointed to Amicus's solid financials—including a 90.6% gross margin and a current ratio of 3.34—and growing confidence in patient shifts toward PomOp over Nexviazyme/Lumizyme. Morgan Stanley adjusted its sales forecasts slightly below consensus for Galafold and PomOp, but remains bullish due to Amicus's recent licensing of DMX-200 for FSGS treatment. With strategic supply chain planning and U.S. inventory in place, management expects minimal tariff impact in 2025, reinforcing the company's operational resilience. Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a global biotechnology company that develops and delivers transformative medicines for people living with rare metabolic diseases. It leverages innovative technology platforms to create treatments for genetic diseases, with a strong emphasis on patient needs. While we acknowledge the potential of FOLD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data